Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research

Objectives This study aimed to develop consensus on an internationally agreed dataset for juvenile dermatomyositis (JDM), designed for clinical use, to enhance collaborative research and allow integration of data between centres. Methods A prototype dataset was developed through a formal process that included analysing items within existing databases of patients with idiopathic inflammatory myopathies. This template was used to aid a structured multistage consensus process. Exploiting Delphi methodology, two web-based questionnaires were distributed to healthcare professionals caring for patients with JDM identified through email distribution lists of international paediatric rheumatology and myositis research groups. A separate questionnaire was sent to parents of children with JDM and patients with JDM, identified through established research networks and patient support groups. The results of these parallel processes informed a face-to-face nominal group consensus meeting of international myositis experts, tasked with defining the content of the dataset. This developed dataset was tested in routine clinical practice before review and finalisation. Results A dataset containing 123 items was formulated with an accompanying glossary. Demographic and diagnostic data are contained within form A collected at baseline visit only, disease activity measures are included within form B collected at every visit and disease damage items within form C collected at baseline and annual visits thereafter. Conclusions Through a robust international process, a consensus dataset for JDM has been formulated that can capture disease activity and damage over time. This dataset can be incorporated into national and international collaborative efforts, including existing clinical research databases.

[1]  J. Treat,et al.  Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists , 2017, The British journal of dermatology.

[2]  P. Lachenbruch,et al.  2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative In , 2017, Arthritis & rheumatology.

[3]  P. Lachenbruch,et al.  2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis , 2017, Annals of the rheumatic diseases.

[4]  L. Rider,et al.  Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease , 2017, Pediatric Rheumatology.

[5]  Jane M Blazeby,et al.  ORAL PRESENTATIONS , 1993, European Surgical Research.

[6]  I. Sjaastad,et al.  Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies , 2016, RMD Open.

[7]  P. Williamson,et al.  Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use , 2015, Trials.

[8]  K. Main,et al.  Validity of Self-Assessment of Pubertal Maturation , 2015, Pediatrics.

[9]  J. Gottenberg,et al.  Incidence and prevalence of inflammatory myopathies: a systematic review. , 2015, Rheumatology.

[10]  F. Miller,et al.  Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research , 2014, Current opinion in rheumatology.

[11]  A. Rawat,et al.  Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India , 2014, Clinical Rheumatology.

[12]  L. Wedderburn,et al.  Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research , 2014, Pediatric Rheumatology Online Journal.

[13]  B. Feldman,et al.  Health outcomes of pediatric rheumatic diseases. , 2014, Best practice & research. Clinical rheumatology.

[14]  A. Martini,et al.  PReS-FINAL-2012: Introducing a new approach to clinical care of juvenile dermatomyositis: the juvenile dermatomyositis multidimensional assessment report , 2013, Pediatric Rheumatology.

[15]  I. Lundberg,et al.  Registries in idiopathic inflammatory myopathies , 2013, Current opinion in rheumatology.

[16]  J. Malley,et al.  The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies , 2013, Medicine.

[17]  A. Reed,et al.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis , 2011, Nature Reviews Rheumatology.

[18]  R. Ramsey,et al.  Measures of general pediatric quality of life: Child Health Questionnaire (CHQ), DISABKIDS Chronic Generic Measure (DCGM), KINDL‐R, Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales, and Quality of My Life Questionnaire (QoML) , 2011, Arthritis care & research.

[19]  A. Reiff,et al.  Preliminary criteria for global flares in childhood‐onset systemic lupus erythematosus , 2011, Arthritis care & research.

[20]  R. Schneider,et al.  Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. , 2011, Rheumatology.

[21]  M. Urowitz,et al.  International consensus for a definition of disease flare in lupus , 2011, Lupus.

[22]  L. Wedderburn,et al.  A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies , 2010, Rheumatology.

[23]  N. Wulffraat,et al.  The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis , 2010, Arthritis care & research.

[24]  P. Mathiesen,et al.  Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. , 2010, Clinical and experimental rheumatology.

[25]  B. Lie,et al.  Long‐term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case–control study , 2010, Arthritis care & research.

[26]  A. Martini,et al.  Long‐term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients , 2010, Arthritis care & research.

[27]  I. Sjaastad,et al.  Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. , 2009, Rheumatology.

[28]  S. Prahalad,et al.  Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. , 2009, Arthritis and rheumatism.

[29]  B. Feldman,et al.  Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood , 2008, The Lancet.

[30]  A. Paller,et al.  Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. , 2008, Arthritis and rheumatism.

[31]  L. Wedderburn,et al.  The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. , 2006, Rheumatology.

[32]  B. Feldman,et al.  An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). , 2006, Rheumatology.

[33]  L. Wedderburn,et al.  Paediatric idiopathic inflammatory muscle disease: recognition and management. , 2005, Drugs.

[34]  C. Duffy Health outcomes in pediatric rheumatic diseases , 2004, Current opinion in rheumatology.

[35]  N. Jones,et al.  Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire , 1993, Quality of Life Research.

[36]  W. Kuis,et al.  Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. , 2003, Rheumatology.

[37]  P. Lachenbruch,et al.  Defining Clinical Improvement in Adult and Juvenile Myositis. , 2003, The Journal of rheumatology.

[38]  B. Feldman,et al.  Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. , 2002, Rheumatic diseases clinics of North America.

[39]  D. Isenberg,et al.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. , 2001, Rheumatology.

[40]  B. Feldman,et al.  Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. , 2000, Arthritis and rheumatism.

[41]  B. Feldman,et al.  Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. , 2000, The Journal of rheumatology.

[42]  G. Bonsel,et al.  Test-retest reliability of health state valuations collected with the EuroQol questionnaire. , 1994, Social science & medicine.